ASSESSING RISKS to the LIVES of Canada’s INDIGENOUS WOMEN

In a 1200 word report issued June 3, 2019, Canada’s federal government acknowledged a horrifying statistic: Canada's Indigenous women are at least six times more likely to become victims of homicide than non-Indigenous women: https://www.cbc.ca/news/politics/mmiwg-inquiry-deliver-final-report-justice-reforms-1.5158223 In addition, we should acknowledge that Canada's Indigenous people are at least five times more at risk of acquiring hepatitis C, and that

CONTAMINATED BLOOD SCANDAL HEARINGS finally being held in UK

Links follow to some really amazing "lived experience" stories from the recent UK inquiry, by British people who contracted hepatitis C from contaminated blood products and transfusions, including some stories from their families. They have waited many years for these hearings. https://www.bbc.com/news/topics/c6gz70808ext/uk-contaminated-blood-scandal

FDA approves first treatment for all HCV genotypes in CHILDREN (USA)

FDA approves MAVYRET™, the first treatment for all genotypes of hepatitis C approved by this US agency for pediatric use. On behalf of Canada's children, we hope Canada will soon follow (Canada's version of AbbVie's hepatitis C drug is spelled Maviret™)! For Immediate Release, April 30, 2019 https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients

FREE Seminar in HCV Elimination among Men Who Have Sex with Men (MSM)

Clinical Care Options presents three new seminars in their HCV Elimination 2018 series, each one dealing with a population particularly at risk of acquiring or passing on HCV: Men Who Have Sex with Men [MSM] - ACCESS INFORMATION BELOW Persons Who Inject Drugs [PWID] - SEE ACCESS INFORMATION IN SEPARATE ARTICLE, and People Who Are Incarcerated [COMING SOON] The MSM module is introduced below... CCO CME/CE-certified interactive video module

FREE Seminar in HCV Elimination among Persons Who Inject Drugs (PWID)

Clinical Care Options presents three new seminars in their HCV Elimination 2018 series, each one dealing with a population particularly at risk of acquiring or passing on HCV: Persons Who Inject Drugs, [PWID] - ACCESS INFORMATION BELOW. Men Who Have Sex with Men [MSM] - SEE ACCESS INFORMATION IN SEPARATE ARTICLE, and People Who Are Incarcerated [COMING SOON] The PWID module is introduced below... CCO CME/CE-certified interactive video modu

BC PharmaCare lists Maviret™ treatment for HCV

Congratulations, hepatitis C patients in BC, BC PharmaCare, and AbbVie Pharmaceuticals! One more treatment option is now available to BC HCV patients of all genotypes, New patients without cirrhosis need only 8 weeks treatment. Maviret™ is also safe and effective for the many HCV+ people with chronic kidney disease (CKD). More information: https://www.newswire.ca/news-releases/british-columbia-pharmacare-lists-abbvie-s-hepatitis-c-treatment-mavi...

The Week in Review: Jan. 25, 2019 – Feb. 22, 2019

Friday, Feb. 22, 2019 News Recap: Time to Change Protocols for Post-SVR Monitoring for Liver Cancer? In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019) Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV) MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring

No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring Protocols?

Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV. HepCBC's volunteer Webmaster, CD Mazoff, PhD (discourse analysis, McGill), is battling liver cancer (HCC). For several years, CD has faithfully published the online HepCBC Weekly Bull every Friday, showcasing Ca

The Week in Review: Jan. 18, 2019 – Jan. 25, 2019

Friday, Jan 25, 2019 News Recap: Using Telemedicine HCV Care Model in Prisons in SPAIN “HCV telemedicine program satisfying, cost-effective in Spanish prison:  A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018…” Read more about Spain’s prison-based HCV “Telemedicine” treatment model. Saturday in Surrey! Visit HepC

Using Nurse-led HCV Care Model in Prisons in AUSTRALIA

“Nurse-led HCV care model results in 95% or higher SVR rates in prison: A decentralized, nurse-led model of hepatitis C care with direct-acting antivirals was significantly effective and led to high levels of sustained virologic response in a large cohort of inmates, according to a recently published study…” Read more... https://www.healio.com/hepatology/hepatitis-c/news/online/%7B33a10536-2c18-4632-9f19-995fafe9dd16%7D/nurse-led-hcv-care-model-results-in